Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation: Endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized Electrocardiology

. Author manuscript; available in PMC: 2011 Mar 15.

Published in final edited form as: J Am Coll Cardiol. 2010 Mar 2;55(9):934–947. doi: 10.1016/j.jacc.2010.01.001

Disclosures Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers’ Bureau/ Honoraria	Expert Witness	Ownership Interest	Consultant/ Advisory Board	Other
Barbara J. Drew	University of California San Francisco	GE Healthcare^†; Philips^†	None	GE Healthcare^; Philips^	None	None	None	None
Michael J. Ackerman	Mayo Clinic	None	None	None	None	None	Boston Scientific^; Medtronic^; PGxHealth^†; St. Jude Medical Inc.^*	Royalty payments from Mayo Clinic from the licensing of technology to PGxHealth for their FAMILION genetic tests^†
Marjorie Funk	Yale University	Philips Healthcare^*	None	GE HealthCare^; Philips Healthcare^	None	None	None	None
W. Brian Gibler	University of Cincinnati College of Medicine	Abbott POC/i-STAT^†; Bristol-Myers Squibb^†; Sanofi-Aventis^†; Schering Plough^†	None	None	None	Inovise^; Siloam^	ArgiNOx^; Astellas^; AstraZeneca^; Daiichi Sankyo/ Lilly^; HeartScape Technologies^; Schering Plough^; Sanofi-Aventis/ Bristol-Myers Squibb^*	Unrestricted educational grant support from Abbott POC/i-STAT^†; ArgiNOx^†; Biosite^†; Bristol-Myers Squibb^†; Daiichi Sankyo/Lilly^†; Inovise^†; The Medicines Co^†; Millennium Pharmaceuticals, Inc^†; PDL BioPharma^†; Roche Diagnostics^†; Sanofi- Aventis^†; Scios^†
Paul Kligfield	Cornell Medical Center	None	GE Healthcare^; Mortara Instrument^; Philips Medical^*	None	None	None	Cardiac Science^; MDS Pharma^	None
Venu Menon	Cleveland Clinic Foundation	None	None	Roche Datascope^*	None	None	Medicure^*	None
George J. Philippides	Boston University Medical Center	None	None	None	None	None	None	None
Dan M. Roden	Vanderbilt University School of Medicine	None	None	St. Jude^*	None	None	Adolor^; ARCA^; AstraZeneca^; Avanir^; Cardiome^; CardioDx^; Eli Lilly^; Novartis^†; Ortho Diagnostics^; Sanofi^*	Patent payment (royalty) from Vanderbilt/Clinical Data (formerly Genaissance)^*
Wojciech Zareba	University of Rochester	None	None	None	None	None	Biogen^; Durect^; Genzyme^†; Cardiac Technologies^† (offshoot of University of Rochester)	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if 1) the person receives $10 000 or more during any 12-month period or 5% or more of the person’s gross income; or 2) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

Modest.

^†

Significant.